By inventing an innovative diagnostic device, researchers at the University of Notre Dame have taken an important step towards early and accurate diagnosis of glioblastoma brain cancer. This device is able to detect the existence of this type of aggressive cancer by using a small blood sample and in a short period of time.
According to the medical and health news department of Tekna Technology Media, glioblastoma is one of the most dangerous types of brain tumors that grow rapidly and aggressively. Late diagnosis of this disease greatly reduces the chances of patients’ recovery. The traditional method of diagnosing glioblastoma is brain biopsy, which is an invasive procedure with side effects.
A new device developed by researchers at the University of Notre Dame is able to detect specific biomarkers associated with glioblastoma using a small blood sample. This device uses a small biochip equipped with an electrokinetic sensor that is able to identify and separate very small particles called extracellular vesicles. These vesicles contain specific proteins that are significantly increased in glioblastoma patients. This device is able to detect glioblastoma in the early stages and before the appearance of clinical symptoms. Also, unlike brain biopsy, this method does not have any side effects for the patient. Test results are available in a short period of time and with high accuracy.
The electrokinetic sensor in the device attracts the charged particles in the blood sample using an electric field. Extracellular vesicles that contain glioblastoma biomarkers are separated from other blood components and identified by this method. The development of this diagnostic device will create a huge change in the diagnosis and treatment of glioblastoma. With the early diagnosis of this disease, it is possible to treat more effectively and increase the chance of recovery of patients. Also, this technology can be used in the diagnosis of other types of cancer.
To see the latest news, refer to the scientific news page of Tekna Media.
RCO NEWS